# Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

> **NCT06212076** · PHASE1,PHASE2 · RECRUITING · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** IPG1094

## Key facts

- **NCT ID:** NCT06212076
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-11
- **Primary completion:** 2027-07-09
- **Final completion:** 2027-07-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212076, "Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06212076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*